BronchogenvsVilon

Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.

For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.

As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed as part of the Khavinson peptide bioregulator program, designed to mimic the immune-regulatory effects of thymic peptides in the shortest possible amino acid sequence. As a dipeptide, it is one of the smallest molecules proposed to have specific gene-regulatory activity — which is both its appeal (simplicity, stability, oral bioavailability) and the source of scientific skepticism (whether a two-amino-acid molecule can have specific transcriptional effects).

Vilon is proposed to regulate thymic function and T-cell immunity through the peptide bioregulator mechanism: penetrating cell membranes, entering the nucleus, and interacting with specific DNA sequences in immune-related gene promoters. The reported effects include enhanced T-cell differentiation from thymic precursors, improved balance between CD4+ helper and CD8+ cytotoxic T cell populations, and modulation of cytokine production toward a more balanced Th1/Th2 immune profile.

Preclinical and clinical studies from the Khavinson group have reported that Vilon treatment enhances immune surveillance (the ability of the immune system to detect and eliminate abnormal cells), improves vaccine responsiveness in elderly subjects, and partially reverses age-related immunosenescence markers. In combination with Epithalon (another Khavinson bioregulator targeting telomerase and the pineal gland), Vilon was reported to reduce mortality in a long-term follow-up study of elderly subjects in St. Petersburg. The proposed mechanism for immune enhancement involves restoration of thymic peptide signaling that declines with age-related thymic involution, essentially providing a minimal molecular signal that tells immune progenitor cells to differentiate and mature. As with all Khavinson bioregulators, independent validation through Western clinical trial standards is still needed.